Cargando…
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication
Interferon alpha (IFN-α)-based therapy is the currently approved treatment for chronic hepatitis C viral infection. The sustained antiviral response rate is approximately 50% for genotype-1 infection. The major challenge to the HCV community is to improve antiviral efficacy and to reduce the side ef...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232870/ https://www.ncbi.nlm.nih.gov/pubmed/16146571 http://dx.doi.org/10.1186/1743-422X-2-80 |